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Evidence-Based Medicine 
And the Law: The Courts Confront 
Clinical Practice Guidelines
Arnold J. Rosoff
University of Pennsylvania
Abstract This article examines how courts are likely to apply evidence-based med-
icine, and particularly clinical practice guidelines (CPGs), in healthcare litigation
involving quality-of-care and entitlement-to-benefits (coverage) claims. Exploring
the “politics” of the current situation, it observes that, just as clinicians have been
reluctant to use CPGs in practice, courts have been, and likely will continue to be,
slow to apply them in deciding cases., The article analyzes extant and proposed statu-
tory approaches to legitimizing and promoting courts’ use of CPGs. It concludes by
renewing the author’s earlier and controversial proposal to establish a voluntary fed-
eral program for certifying guidelines and directing courts to give certified CPGs
greater weight in healthcare litigation.
The Advent of Evidence-Based Medicine
The past few decades have seen tremendous and exciting strides in the
development of evidence-based medicine (EBM), defined as the consci-
entious, explicit, and judicious use of current best evidence in making
decisions about the care of individual patients (see Cynthia D. Mulrow
and Kathleen N. Lohr in this issue).1 Medicine, long recognized as a sub-
tle admixture of science and art, has moved notably in the direction of an
exact science as new tools and techniques have been developed to help
practitioners of “the healing arts” understand better what works in the
treatment of patients. This dramatic expansion of medical knowledge,
and of the ways by which medical knowledge is advanced, is changing
the face of medical practice.
Journal of Health Politics, Policy and Law, Vol. 26, No. 2, April 2001. Copyright © 2001 by Duke
University Press.
1. Mulrow and Lohr cite Sackett et al. 1997, as the source of this definition. 
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A key aspect of this change has been the development of outcomes
research, for systematic and large-scale study of the effects different
diagnostic tools or therapies have when applied to large numbers of
patients (see U.S. Congress 1994; Roper et al. 1988; Havighurst 1990).
Facilitated by the widespread use of computers to record and analyze
medical data and the standardization of encounter and treatment data,
outcomes research is increasingly making it possible to know more pre-
cisely and certainly what is, and is not, effective therapy. 
Many in the health care community have welcomed this advance of
knowledge, but some see a potential downside for professional autonomy.
When more is known about the “right” way to treat a particular condi-
tion, there is less latitude for individual judgment. Clinicians, historically
accorded wide latitude for the exercise of personal discretion in choosing
treatments for their patients, now feel increasing pressure to conform to
established norms of treatment. Much of that pressure comes from man-
aged care organizations (MCOs) and health plans, both private and gov-
ernmental, all pursuing an agenda of aggressive cost containment. More-
over, in an environment supportive of EBM, a clinician might more
readily be held accountable for a poor outcome if it can be attributed to
deviation from an EBM-based prescribed treatment approach. For this
reason, EBM is seen by some as packing a one-two punch: erosion of
autonomy going into a treatment situation accompanied by greater risk
of liability after the fact. It’s no wonder, then, that some parts of the med-
ical community view EBM as a mixed blessing.
A major way that EBM has impacted medical practice has been through
the development, dissemination, and use of clinical practice guidelines
(CPGs). The Institute of Medicine’s widely cited 1990 report defines
CPGs as “systematically developed statements to assist practitioner and
patient decisions about appropriate health care for specific clinical cir-
cumstances” (Field and Lohr 1990). CPGs can be used to guide practi-
tioners in undertaking treatment of various kinds of conditions and to
help third-party payers, regulatory bodies, and courts determine whether
care given in a particular instance was adequate and appropriate. Thus
CPGs have relevance both for the practice of medicine by physicians and
for the regulation of that practice by others. 
A brief word about terminology: Because CPGs are the most common
practical embodiment of EBM, the terms “clinical practice guidelines”
and “evidence-based medicine” and their acronyms have often been used
interchangeably, or nearly so. Daniel W. Shuman’s essay in this sympo-
sium issue treats them this way; this article will too. It should be under-
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stood, however, that they are distinct terms and can be used in contexts
where they are not interchangeable. EBM can show up in forms other
than CPGs—for example, in journal articles, unpublished studies, and
expert testimony. Conversely, CPGs are not necessarily based upon
EBM—although the vast majority of the CPGs being generated nowa-
days are, or at least purport to be. Cynthia Mulrow and Kathleen Lohr’s
essay recognizes that guidelines generated primarily through a pro-
fessional consensus process—the traditional approach—may differ from
those based more directly on hard, empirical evidence—the EBM
approach. This last point is especially important, because courts, in
deciding what weight to accord to CPGs, may find it useful, even neces-
sary, to distinguish between those that are based on EBM and those that
are not.
Building on professional reservations about EBM generally, growth in
the development and use of CPGs has fueled concern in some quarters
about their implications for medical practice. Some decry the spread of
CPGs as the advent of “cookbook medicine,” having the potential to turn
doctors into automatons and lower the quality of health care by subordi-
nating and subverting professional skill and judgment. While many of the
changes to be expected from EBM and CPGs are positive and should be
welcomed and facilitated, the political climate for their acceptance, dis-
cussed below, is far from assured.
For the balance of this section, this essay lays a foundation by dis-
cussing in general terms how courts might benefit from the use of EBM,
especially in the form of clinical practice guidelines, and by examin-
ing, again in general terms, why and how courts might have difficulty in
adopting and using CPGs. In the second section, the essay examines var-
ious ways courts might employ CPGs in handling quality-of-care and
entitlement-to-benefits cases. Courts’ actual experience with litigation
involving CPGs is highlighted, as is emerging legislation that defines how,
and by whom, CPGs may be used in litigation. A third section explores
the “politics” of EBM and CPGs, considering how political and cultural
forces in the health care, legal, and public policy communities may bear
upon the rules legislatures and courts apply to govern the use of this type
of evidence. Finally, the essay concludes with a proposal I put forward
some five years ago (Rosoff 1995) for the development of a governmen-
tal certification program for CPGs. The essential notion is that, in the face
of multiple, competing guidelines for treating particular conditions,
courts could benefit greatly from some mechanism, presumably govern-
mental, that would help them sort credible and authoritative guidelines
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from those not so deserving of the courts’ acceptance. While numerous
factors, some of them “political,” in different meanings of that term, cut
against the establishment of a certification program, I continue to believe
the idea has merit and deserves further consideration. 
The Law’s Acceptance of Evidence-Based 
Medicine
In addition to professional reactions to EBM, how the law regards and
treats EBM will also greatly affect the pace and nature of its acceptance.
There are troubling indications that the courts haven’t figured out yet
how to deal with medical evidence in a variety of contexts. A great deal
has been written about the distorting effects of “junk science” in litigation
concerning silicon breast implants, various drugs and medical devices,
such as Bendectin and IUDs, toxic torts, and other controversies involv-
ing scientific evidence. Popular books of the past few years—such as
David Faigman’s Legal Alchemy: The Use and Misuse of Science in the
Law (1999) and Marcia Angell’s Science on Trial: The Clash of Medical
Evidence and the Law in the Breast Implant Case (1997)—raise disturb-
ing doubts about how often the courts can “get it right” when dealing
with evidence of this nature. The great promise of EBM to improve the
quality of care, help contain health care costs, reduce disputes about cov-
erage under health plans, and ease the financial and other burdens of
medical malpractice litigation on the health care system may be compro-
mised if the law is unsure or confused about how to deal with EBM.
How, then, can we move most effectively toward the adoption of desir-
able legal rules and procedures for dealing with evidence-based medi-
cine? The traditional process of generating legal doctrine in a new area
through litigation on an ad hoc, state-by-state basis, as cases happen to
come up, is too haphazard and slow to be adequate for a matter as impor-
tant, volatile, and fast-moving as the adoption and use of EBM. As noted
above, this essay considers some approaches that have been tried in an
effort to accelerate EBM’s assimilation into the law and, toward that
same end, offers the author’s proposal for certification of clinical practice
guidelines.
The Uses of Medical Evidence in the Courts
In general, people are enthusiastic about the prospect of developing bet-
ter tools that will enable them to do their jobs more efficiently and effec-
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tively. When faced with the reality of new tools, however, this enthusi-
asm often is diminished by the challenges of improving skill levels. Once
a new tool is mastered, the investment in gearing up to use it may “pay
for itself” many times over, either by saving future time and effort or by
making possible a better product or service. In the short run, though,
adoption of new approaches can generate more cost than benefit. This
may well be the case with the emerging use of EBM by the courts. EBM
applications may ultimately make it much easier for courts to resolve
health care disputes; but, in the short run, the courts will have to learn
new principles and develop new rules for applying them in the litigation
context. There will undoubtedly be challenges to those rules. An impor-
tant objective of the symposium that spawned these essays was to help
assure that the legal system’s balance sheet on EBM comes up positive at
the earliest time possible.
To discuss how the legal system will treat new forms of medical evi-
dence, it is necessary to recognize that such evidence is used by the
courts in a number of different contexts. Within the frame of the present
discussion, two main categories of use are relevant: challenges regarding
the quality of care (the principal subject of medical malpractice litiga-
tion) and challenges regarding the determination of what benefits are
covered under a health plan in a given instance. Federal courts have
struggled for several years to sort out these two classes of issues in cases
involving the scope of federal preemption under ERISA, the Employee
Retirement Income Security Act of 1974 (29 United States Code 1001, et
seq.) (see Dukes v. U.S. Healthcare, 57 F.3d 350 [3d Cir. 1995]; Mariner
1996, 2000). Under managed care, these two sets of issues, though 
historically separate, increasingly tend to be intertwined. With growing
frequency, suits are filed claiming that the quality of care was inade-
quate because benefits owed under the plaintiff’s health plan were
withheld, either with or without the plaintiff’s knowledge at the time.
Both quality-of-care and coverage cases involve common issues that
are typically addressed through the testimony of medical expert wit-
nesses. The main issues commonly calling for expert testimony are: (1)
the applicable standard of care, (2) causation (the connection between
the alleged wrongful conduct and the harm suffered by the plaintiff ),
and (3) the assessment of damages, which often involves (4) medical
prognosis. 
The type of issue involved dictates the nature and scope of the expert
witness’s input. The last three of these issues—causation, assessment of
damages, and prognosis—usually require the expert witness to apply his
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or her expertise directly to the question at hand.2 The first of the four
issues, the standard of care, is different, however. On this point, an expert
is supposed to testify not as to what she or he thinks is the proper way to
treat the case at hand but, rather, as to what others in the profession com-
monly would do in such a situation. The expert’s testimony is focused
this way because courts usually measure the adequacy of a patient’s treat-
ment by its conformity to standard practice in the relevant medical com-
munity, the so-called professional community standard. Thus, in this
context—different, perhaps, from all others in which medical experts are
called to testify—the expert’s contribution is not his own scientific judg-
ment or expertise about how best to handle a clinical situation but, rather,
his or her knowledge of how professional peers commonly handle simi-
lar situations. This difference in the treatment of standard-of-care issues
is important to the present discussion because, as explained below, a
court uses a CPG to establish the legal standard of care, obviating the
need for expert testimony on that point. By contrast, even where a CPG
contains information relevant to causation, assessment of damages, or
prognosis, it is hard to see how a court could make use of this informa-
tion without the accompanying testimony of a medical expert witness.
For this reason, and because the main object of CPGs is to set a standard
of care, the present discussion addresses only those situations where
CPGs are used to help determine the legal standard of care to be applied
in the case being litigated. Belying the assertion just made about what the
main object of CPGs is, for reasons of professional politics and in con-
templation of litigation, guidelines developers routinely disclaim that
their recommendations are “standard-setting.” Despite these protesta-
tions, it remains an open question whether, and to what extent, courts
will treat CPGs as setting the legally required standard of care.
Problems with New Tools 
Will the explosion of medical evidence and CPGs be a help or a hin-
drance to the courts? On the one hand, better evidence might make it eas-
ier for courts to reach accurate determinations in a difficult technical
area. On the other hand, the profusion of evidence, seemingly or actually
332 Journal of Health Politics, Policy and Law
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in your expert opinion, based upon your knowledge and personal experience, do you believe that
the defendant’s acts (or omissions) caused the plaintiff’s injury?” Similar examples could be
offered involving assessment of damages [“Doctor, how serious is the patient’s injury? In your
view, is this a case of “total disability?”] and prognosis [“Doctor, in your opinion, will the
patient-plaintiff ever again be able to drive a truck?]. 
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inconsistent (e.g., conflicting clinical practice guidelines), could confuse
more than clarify. 
To illustrate with an example, imagine that a forty-five-year-old female
HMO member loses a breast to cancer, which, she claims, could have
been treated successfully if caught earlier by more frequent mammogra-
phy screening. The HMO screened once every two years, following the
guidelines of the National Cancer Institute (NCI) for women in her age
and risk category. The patient-plaintiff rests her case on a contrary guide-
line, issued by the American Cancer Society (ACS), which calls for
screening once a year for women in that category. The jury must decide
whether the doctor and HMO met the standard of adequate care by
screening on the less frequent schedule. Traditionally, before CPGs were
such a part of the picture, the parties in a malpractice case would address
this issue by having medical experts testify on each side as to the profes-
sional community standard—the classic “battle of the experts.” Might
the contest be raised now to a higher level, with the guideline of one
respected professional group pitted against that of another? Will we now
see a “battle of the super-experts?” Clark Havighurst (1991: 95), in his
seminal early exploration of the use of guidelines, observed that “prac-
tice guidelines may only occasionally resolve a dispute crucial in the lit-
igation of an actual malpractice claim.” But, now that the guidelines
movement has gathered another decade’s worth of momentum, that may
be changing. With CPGs routinely playing a central role in the determi-
nation of what care patients receive, it is easy to envision them assum-
ing a more prominent role in fixing the legal standard for measuring the
adequacy of that care—in other words, serving the evidentiary function
traditionally served by live experts. 
If CPGs do come to play a greater role in medical malpractice and
related cases, might a court allow evidence and/or argument to the point
that one guideline-generating organization was entitled to more respect
than the other or that one set of guidelines was more credible because
better supported by the underlying data or by a more robust methodology
for outcomes research, possibly including cost-effectiveness analysis
(CEA) (see Peter D. Jacobson and Matthew L. Kanna in this issue)?
Might the court allow the parties to lead the jury through the mechanics
and nuances of EBM research and guideline generation? Might one party
try to show that, whereas its guideline was based on solid, up-to-date
empirical data, its opponent’s older guideline was developed through a
more subjective, consensus-based process and, thus, was less valid? Such
evidence, while it might fascinate a jury, would likely have great poten-
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tial to confuse it. Under the principle of Daubert v. Merrell Dow Phar-
maceuticals [509 U.S. 579 (1993)], as described in Shuman’s article in
this issue, a trial judge is required to prescreen scientific evidence and
admit only that which is likely to inform the jury and not confound it. In
pursuing this obligation, might the judge bar this entire line of inquiry?
Might she simply make an initial determination as to whether each of the
proffered CPGs was authoritative enough to be admitted and then let
them go to the jury on equal footing even though she believed one to be
notably more sound—i.e., better conceived or based on stronger sci-
ence—or more reputationally authoritative than the other? It is clear
that the court’s job in managing health care litigation may be signifi-
cantly more complex in the face of the better knowledge and evidence
that EBM makes possible than it would have been previously in “less
enlightened” times. (It should be noted that the Daubert ruling applies
only in cases controlled by the Federal Rules of Civil Procedure and
those in states that have adopted the principle of Daubert.) 
Assuming, for the sake of argument, that a savvy trial judge under-
stands enough about CPGs to make wise rulings about how they should
be handled as evidence, there still is likely to be controversy around such
rulings until they are validated on appeal. Novel procedural rulings, such
as those involving the admissibility and significance of new kinds of evi-
dence, routinely invite challenges. (As has happened before in health
care, and other fields, courts may be hindered in reaching important sub-
stantive issues because they first have to formulate new definitional and
procedural rules and have them tested and approved. Consider, for exam-
ple, the protracted haranguing over the use and validity of DNA evidence
in the criminal trial of O. J. Simpson.) An example of this phenomenon,
addressed in the Shuman essay, is the treatment of expert testimony in
litigation involving medical and scientific matters (e.g., products liability,
toxic tort, etc.). Other examples in the health care field include cases
involving contractual arbitration in health care (Madden v. Kaiser Foun-
dation Hospitals, 552 P.2d 1178 [Cal. 1976]; Rosoff 1986) and the use of
pretrial screening panels for medical malpractice cases (Macchiaroli
1990; Carlin 1980; Institute of Medicine 1978). Issues will inevitably
arise as courts pick their way through the question of how to handle
CPGs as evidence. Challenges will address not just the admissibility of
and weight to be accorded to CPGs but also whether the use of CPGs is
allowed to both plaintiffs and defendants on an equal basis, an issue dis-
cussed below. 
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Clinical Practice Guidelines in the Courts
U.S. courts have only just begun to figure out how to deal with clinical
practice guidelines (CPGs). To date, most of the litigation about CPGs
has involved claims of medical malpractice. Going forward, it is likely
that CPGs will also figure prominently in suits involving coverage deci-
sions made under health plans. The relatively few courts that have dealt
with CPGs have varied widely in their treatment as evidence. In some
instances, CPGs have simply been deemed inadmissible. For example, a
1995 Maryland statute enacted to encourage guidelines development pro-
vided that CPGs developed under the program it established could not be
used in litigation (Md. Code Ann. [Health-Gen.] Section 19-606), a
restriction that has since been removed from the legislation. In future
cases, pursuant to state legislation fostering CPG development and use,
some courts will admit them only for use by the defense. Even where
they can be introduced by both parties to a litigation, there is a range of
alternatives as to how much weight they will be given. Certainly, it will
be some time before there are settled conventions for the use of CPGs
and for instructing juries on the matter.
The Importance of Federal Law
The analysis in the following section builds upon state law foundations
and assumes the role of CPGs will be determined as a matter of state law.
Medical malpractice has historically been a matter of state law and not
subject to federal control. For that reason, federal courts have rarely been
involved, except in diversity of citizenship cases, that is, where a citizen
of one state sues a citizen of another state and the amount in controversy
exceeds a statutory threshold, currently $75,000. In diversity cases, the
U.S. Supreme Court’s ruling in Erie R. R. Co. v. Tompkins (304 U.S. 64
[1938]) requires federal courts to follow the applicable state law, if there
is any. In cases before them on whatever jurisdictional ground, however,
federal courts largely apply their own rules of procedure. Thus, to the
extent that the treatment of CPGs is regarded as an evidentiary (proce-
dural) matter, federal courts are free to fashion rules regarding their
admissibility, rules of application, weight, and so on. If, on the other
hand, the use of CPGs is deemed to be substantive rather than proce-
dural, federal courts would be bound to follow state law or, in the absence
of controlling state law, to treat CPGs as they predict courts in the rele-
vant state would if the same case were tried there. In this author’s pro-
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posal for a federal program to certify CPGs, the assumption that state law
would control is, for the most part, set aside. 
There is ample precedent for extending federal control beyond its tra-
ditional limits through “carrot and stick” initiatives, whereby adherence
to federal law, or federal standards for state law, is the statutory quid 
pro quo for receiving federal funds. The federal health care programs,
Medicare and Medicaid, are examples of this in general. As a more con-
crete example, hospitals that participate in Medicare and operate an
emergency department are required by the Emergency Medical Treat-
ment and Active Labor Act (EMTALA) (42 United States Code Anno-
tated, Section 1395dd [1985]) to provide initial assessment, advice, and
treatment until the patient’s condition is “stabilized,” as defined in the
legislation. The obligation applies whether or not the individual in ques-
tion is covered under the federal program. Presumably, something simi-
lar might be undertaken in the present instance, if adequate political sup-
port for a federal CPG program could be developed. Note, however, that
such a change would raise significant issues of statutory and constitu-
tional law. The division of authority and responsibility for financing, pro-
viding, and regulating health care involves complex questions of states’
rights and separation of powers. It also implicates important federal
statutes, such as the McCarran-Ferguson Act (15 United States Code
1011, et seq. [1945]) and the Employee Retirement Income Security Act
(ERISA) (29 United States Code 1001, et seq. [1974]). Further consider-
ation of the role of federal law is reserved for the later discussion of the
proposed certification program; the rest of this section assumes that state
law controls.
Admissibility and Weight Given 
to Clinical Practice Guidelines
There are various approaches state courts could take with regard to clin-
ical practice guidelines in the context of medical malpractice litigation.
The treatment of CPGs obviously will depend on the underlying legal
terrain in each state. There is substantial commonality among the states
with regard to their definitions of medical negligence and the evidentiary
requirements for proving and defending against malpractice claims.
However, there are differences among the states that, while subtle and
occasionally largely semantic, may yet be quite significant. The possibil-
ities set forth below are not mutually exclusive; a court could adopt a
treatment of CPGs that combines elements of two or more of them. 
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As Evidence of Customary Practice. A core principle in medical malprac-
tice litigation followed in most, but not all, cases is that the legal standard
of care is set to customary practice in the relevant medical community,
the so-called professional community standard. Thus, in most jurisdic-
tions, under most circumstances, adherence to prevalent professional
standards is an adequate defense to a claim of medical negligence. The
most obvious possibility for the use of CPGs, then, is that a court could
look to them as evidence of what is customary practice in the medical pro-
fession. A physician who practiced in conformity with a CPG would be
shielded from liability to the same extent as one who could establish that
she or he followed professional custom. Conversely, a physician’s failure
to conform to a recognized guideline could raise an inference that she or
he did not perform up to the required standard; at the least, it would
obligate the physician to explain why the CPG was not followed.
The main problem with treating CPGs as evidence of professional cus-
tom, however, is that in the case of a newly developed guideline, the treat-
ment approach it calls for may differ, perhaps substantially, from pre-
vailing practice in the profession. This is particularly likely in the case
of cost-reducing guidelines that have evolved from EBM studies that
conclude that the conventional practice “overtreats” the patient and
wastes resources without yielding discernible or sufficient benefit in
terms of better treatment outcomes. As noted above, some CPGs are
developed through a consensus process, in which the treatment recom-
mendations are an amalgam of contemporary professional belief and
practice. Other CPGs are generated through a more scientific, EBM-
oriented process, in which the foundation is rigorous analysis of empiri-
cal outcomes data rather than the cumulated beliefs of practitioners. If
admitted as evidence in malpractice litigation, guidelines formulated in
the first way described would generally serve much the same function as
medical expert testimony as to customary practice. The latter type of
CPGs, at least when first disseminated to the medical community, are
much less likely to reflect current professional practice. Such guidelines
are commonly employed in an attempt to change physician practices in
order to make them more cost-effective. As a new guideline gains more
currency and more adherents, it will increasingly become synonymous
with customary practice. In the short run, however, it is likely to be just
the opposite, a statement of what the profession at large currently does
not do. Thus, so long as courts use “customary practice” to set the legal
standard for acceptable practice, EBM-derived CPGs will be of limited or
questionable utility in the legal system.
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It is instructive to note that CPGs developed from EBM rather than
through a professional consensus process differ in this regard from the
more traditional Medicare utilization review (UR) protocols, which were
statutorily required to be based upon “professionally developed norms of
care, diagnosis, and treatment based upon typical patterns of practice”
(Public Law 92-603, Section 249f, 42 United States Code, Section 1301).
The requirement that Medicare’s UR protocols be derived from custom-
ary professional practice, as revealed in Medicare claims data, undoubt-
edly was driven by political pressure from professional interests. Profes-
sors William Trail and Brad Allen (1995–96: 236–237) draw a different
distinction between what they call “medical practice guidelines” and UR
guidelines. They characterize the latter, pejoratively, as being concerned
only with cost containment and thus having no relevance to quality of
care debates. Havighurst (1990: 778, n.3, citing Lewin and Erickson 1989:
3) acknowledges a similar distinction between “pathway” (quality) guide-
lines and “boundary” (payment) guidelines: “Boundary guidelines are used
by payers to define the range of practice options within which physicians
could act without incurring financial or other sanctions. Pathway guidelines
are employed primarily by providers and serve as a beacon for clinical
practice and a standard around which practice patterns should converge.”
As Evidence of a “Respectable Minority” Approach. A number of states
recognize it as a malpractice defense that the defendant acted in accor-
dance with the custom of at least a “respectable minority,” or recognized
subgroup, of the relevant profession, even though his or her actions were
at odds with mainstream professional practice (Furrow et al. 1997:
198–202). In such a state, a relatively new guideline, although it has not
yet been adopted widely enough to be reflective of “mainstream” prac-
tice, might be sufficiently well accepted to qualify under the “respectable
minority” doctrine. Use of this defense would seem apt where the issuer
of the guideline was a well-established professional society, such as the
American College of Obstetrics and Gynecology (ACOG). However, if
the guideline were the product of an upstart or renegade group, or per-
haps a team of commercial consultants working under contract with an
MCO with the transparent objective of devising ways to reduce costs, it
might be rejected as not representing the position of a “respectable
minority” of the profession.
As Evidence of “Reasonable Prudence.” Adherence to a legitimate CPG
could be treated by the court as evidence of a physician’s “reasonable
prudence,” even if it were not established that a substantial number of
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physicians had yet applied the guideline’s approach in clinical practice.
Some courts define the physician’s legal obligation of due care in terms
of reasonable prudence rather than adherence to professional custom.
This was the approach taken in the Washington Supreme Court’s contro-
versial decision in Helling v. Carey (519 P.2d 981 [Wash. 1974]), which
held that reasonable prudence, not customary professional practice, is
what should be determinative in setting legal standards for medical care.
In so holding, the Helling court cited Judge Learned Hand’s oft-quoted
declaration in The T. J. Hooper (60 F.2d 737, 740 [2d Cir. 1932]) that “in
most cases reasonable prudence is in fact common prudence; but strictly
it is never its measure.” A court following the Helling rationale could
choose to regard a physician’s reasoned compliance with a legitimately
developed CPG as meeting the standard of reasonable prudence.
As Evidence of “Acceptable Practice.” Regardless of the number of prac-
titioners actually following a particular treatment modality at the time, a
court could choose to regard it as “acceptable practice” within the med-
ical community if sanctioned by an appropriate and credible CPG. This
approach, suggested some twenty-five years ago by Professor Joseph
King (1975: 1236), would be very similar to direct application of the
CPG as the applicable legal standard, which is discussed next. It is also
similar in concept to the “respectable minority” doctrine, discussed
above. That is, if the medical community respects a practice as having
been carefully considered and found acceptable by a reputable subset of
the profession, it would not be regarded as improper practice, even if rel-
atively few clinicians had actually adopted it as of the time in question.
The key to the court’s recognition of the CPG as the legal standard
would, in any case, be the medical profession’s acceptance of the CPG
as authoritative. As in the case of the respectable minority doctrine,
acceptance would be affected by the reputation and influence of the
body(ies) developing, endorsing, and/or adopting the CPG. 
As the Legal Standard of Care (Direct Application). The most straight-
forward and complete acceptance of a CPG, of course, would be for a
court simply to treat it as setting the applicable legal standard without
going through any intermediate steps based upon professional acceptance
or customary usage. Giving such direct application to CPGs would be a
substantial departure from existing law and would, presumably, require
legislative action (ibid.: 1235). While this is a simple route conceptually,
it would be a major step politically, since detaching standard setting from
professional consensus has far-reaching implications.
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If a CPG were to be adopted as the legal standard, questions remain
as to how that standard would be applied. Regarding the weight to be
given to it, the most extreme approach would be to treat it as a per se
standard. In other words, it would be conclusively, or irrebuttably, pre-
sumed that the physician was negligent if she or he didn’t follow the stan-
dard and, conversely, that the care was reasonable if she or he did fol-
low it. This is essentially the approach specified in Minnesota’s practice
guidelines legislation, discussed below (Minnesota Statutes, Section
62J.34[3], [1992]). A less prescriptive approach would be to treat com-
pliance with a relevant guideline as raising a rebuttable presumption that
the physician acted correctly; similarly, noncompliance would raise a
rebuttable presumption that the physician acted negligently. Whichever
party asserted the guideline, the opposing party could attempt to counter
this presumption by appropriate evidence. This was the approach con-
templated in the Health Equity and Access Reform Today (HEART) bill,
proposed by Senator John Chafee (R-R.I.) and others in 1993. (S. 1770,
4025, 103d Cong., 1st sess.). Under HEART, adherence to state-devel-
oped guidelines which had been certified by the secretary of Health and
Human Services would raise a rebuttable presumption of appropriate
care that would be overcome only by “clear and convincing evidence,” a
stricter than normal evidentiary standard favoring the party complying
with the guideline. The Chafee bill is significant here because, in the part
just discussed, it bears a close resemblance to the proposal put forward
below for a CPG certification program.
Another dimension to the adoption of a CPG as the legal standard
would be whether that standard is available for use by both the plaintiff
and the defendant. Recent evolution of the use of CPGs as a legal stan-
dard has favored their use only as a defense by the health care provider.
Whether CPGs should be applied in such an asymmetrical manner is con-
sidered below.
Directly applying CPGs as the legal standard for medical care is an
extreme recognition that seems inappropriate and unlikely at this rela-
tively early stage of their development. Public, professional, and judicial
confidence in CPGs would have to be greater than it is currently for them
to be accorded this much weight by the legal system. Before such confi-
dence could be gained, many more issues about CPGs, their auspice,
development, and so on, would have to be addressed and satisfactorily
resolved. Because these conditions have not been met, the American
Medical Association opposes, for the present at least, direct adoption of
CPGs as a legal standard and urges instead that they be used only as evi-
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dence of the customarily observed professional standard of practice and
that their degree of authority be dependent upon the degree of their
acceptance among medical practitioners (American Medical Association
1993: 58; Hirshfeld 1993: 323). As Richard F. Corlin, M.D., testified on
behalf of the AMA (1993: 58): “At the present time, insufficient evidence
exists to show that clinical practice guidelines can be developed in a
manner specific enough to be introduced as an affirmative defense in
medical liability litigation.” It is notable that the AMA’s reservation about
CPGs was stated even in the context of their defensive use.
Courts’ Experience with Clinical 
Practice Guidelines
To date, there has been relatively little litigation using CPGs. Andrew
Hyams, David Shapiro, and Troyen Brennan (1996) did an extensive
computerized legal search covering the period from January of 1980
through May of 1994 and turned up only thirty-seven cases involving
CPGs. This is not to say, however, that CPGs do not figure importantly in
malpractice litigation. A survey of medical malpractice attorneys con-
ducted by Hyams, Shapiro, and Brennan (1996: 292) revealed that about
half of them were aware of practice guidelines and a substantial number
considered guidelines in deciding whether or not to take on malpractice
cases. Guidelines also influenced settlement negotiations in many instances.
Thus prelitigation effects are an important part of the picture, although
such effects do not show up in studies of reported cases.
In principle, although not necessarily in practice, guidelines can be
used in litigation by both patient-plaintiffs and physician-defendants. A
patient-plaintiff can use a CPG for inculpatory (blame-placing, or “sword”)
purposes by establishing that there was an applicable guideline that the
defendant should have followed but did not. Conversely, a defendant can
use a CPG for exculpatory (blame-relieving, or “shield”) purposes by
showing that he or she acted in conformity with an applicable guideline.
In either case, the party asserting the guideline is asking the court to
accept it as proof that the physician either did (shield use) or did not
(sword use) meet the legally required standard of care. 
The studies by Hyams, Shapiro, and Brennan of reported lawsuits
have shown that CPGs are much more commonly used by plaintiffs and,
moreover, that plaintiffs have a notably higher rate of success in litiga-
tion associated with such use. Reports of the lopsided use and effective-
ness of CPGs (Felsenthal 1994) raised alarm within the medical commu-
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nity and reinforced other concerns, noted above, about EBM, including
CPGs. To avoid chilling the progress of CPG development and adoption,
professional interests and legislators have joined in a politics of accom-
modation that threatens to turn CPG use in courts into a “one-way street”
(Hyams, Shapiro, and Brennan 1996: 304). The legitimacy and advis-
ability of this development is addressed in the following section.
Who Can Use Guidelines and for What Purpose?
An important question that clouds the broader consideration of how
CPGs should be treated in the courts is whether both plaintiffs and defen-
dants should be allowed to use CPGs in litigation. Responding to the con-
cerns discussed in the preceding section about CPGs being used more
often and more effectively by plaintiffs, many proponents of CPGs have
successfully lobbied for laws allowing only “shield” use of guidelines by
defendants, sometimes referred to as a “one-way street” approach. The
earliest, and still the principal, example of this uneven application is
Maine’s 1990 Medical Malpractice Demonstration Project (24 Maine
Revised Statutes Annotated, Sections 2971–2978), which set up a five-
year experiment, starting in 1992 and subsequently renewed for another
five years in 1997, authorizing physicians (and their employers) to use
guidelines developed through the project as a shield while prohibiting
their sword use by patient-plaintiffs (see Schanz 1993; General Account-
ing Office 1993). Although this was the clear intent of the legislation,
some have questioned whether it will have this effect in practice. A rep-
resentative of the Maine Trial Lawyers Association (MTLA), which
opposed the experiment before the legislature, has predicted that Maine
courts—driven by constitutional due process and equal protection con-
cerns—will ultimately allow both sides to introduce the guidelines in
malpractice litigation (MTLA 1994: 754). 
Some other states, notably Minnesota, have followed Maine’s lead by
adopting laws providing for only defensive use of practice guidelines
(Minnesota Statutes, Section 62J.34[3][a] [1992]). This was also the
approach of the Clinton administration’s ill-fated Health Security Act
proposal (H.R. 4469, 103d Cong., 2d sess., 1994: 441) and several other
federal health care reform initiatives of the mid-1990s. Florida initiated
a guidelines demonstration project in 1996, roughly similar to that of
Maine but limited to cesarean deliveries, the most common surgical pro-
cedure in Florida hospitals (Florida Statutes, Section 408.02[9]). The
Florida legislation contemplates use of guidelines as a liability shield,
although it doesn’t expressly limit their use to the defense. 
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What has been the experience under these one-sided statutory schemes?
Maine, with the oldest, most fully articulated program, would seem the
most likely to have data to evaluate. In fact, there apparently has been
only one use of the guidelines in a litigation context since Maine’s exper-
iment began in January of 1992. T. Rosser Matthews (1999: 300) observes
that there was only one claim on record (as of December 1997) in which
a physician asserted compliance with an approved guideline as an affir-
mative defense. Earlier reports of the Maine experiment have noted no
constitutional challenges to the program’s asymmetry (MTLA 1994: 753;
General Accounting Office 1993: 19). 
The paucity of malpractice litigation in Maine since the institution of
the state’s CPG experiment is partly due to the fact that the same law that
authorized it also mandated prelitigation screening and mediation pan-
els. These panels are charged to “identify claims of professional negli-
gence that merit compensation and to encourage early resolution of these
claims prior to commencement of a lawsuit” and “encourage early with-
drawal or dismissal of nonmeritorious claims” (24 Maine Revised Statutes
Annotated, Section 2851[1][a][b]). In performing its review, a screening
panel is required to determine if “the defendant complied with an applic-
able parameter or protocol establishing the applicable standard of care”
(ibid., Section 2855[1][a–1]).
Other evidence of the program’s impact, such as a reduction of health
care costs reflecting a lesser incidence of defensive medical practice, is
also inconclusive, although it has been reported that doctors are per-
forming fewer medical procedures prompted by legal considerations
(MTLA 1994: 753). Likewise, the effect of the demonstration project on
malpractice insurance premiums is uncertain. In 1994 the state’s super-
intendent of insurance estimated that the experiment would yield a 0.5
percent savings in malpractice premiums (ibid.). More recently, however,
the Bureau of Insurance reported that it cannot distinguish the impact of
the experiment from other factors affecting medical professional liabil-
ity claim costs and premiums (Matthews 1999: 300). The experiment was
extended for another five years in 1997. However, in a small state like
Maine, with relatively few malpractice suits, it may take longer than that
to gain enough data to fully assess the program’s effectiveness. In fact,
the program may never be able to prove a reduction in the cost of med-
ical care or of malpractice litigation (MTLA 1994: 754). Doctors in the
four specialties originally targeted by the legislation—anesthesiology,
emergency medicine, obstetrics and gynecology, and radiology—have
been supportive of the project. However, other specialties did not take
advantage of a 1993 legislative amendment to expand the project into
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their areas of practice (Chapter 477 of Maine Revised Statutes Annotated;
MTLA 1994: 753).
This uneven application of CPGs has come about as a political barter,
with legislators assuring physicians, in effect, that if they will support 
the development and adoption of guidelines, those guidelines cannot 
be turned against them in litigation (General Accounting Office 1993:
26–27). It is not clear that such protection is needed to jumpstart the
guidelines movement. The potential benefits of and practical pressures
for expanded use of CPGs are so strong and widespread, as are the pres-
sures for managed care generally, that physicians might not be able to
resist them in any event. Still, political deals were struck to foster the
development of guidelines meant to discourage the defensive practice of
medicine (Shuman 1997: 105). Thus, in a number of states that have leg-
islation providing for CPGs, the laws are structured largely for the pro-
tection of providers. 
Should the use of CPGs be a “two-way street,” with this form of evi-
dence available equally to both parties? The answer would appear clearly
to be “yes.” In virtually every other context evidence that is seen as legit-
imate and admissible by the court is allowed on an equal basis to both
parties. Giving providers assurance that guidelines can be used only in
their favor may be an important step toward gaining their support; but
allowing such one-sided use of evidence in a court of law raises disturb-
ing questions of fairness and of validity under the U.S. Constitution’s
Fifth and Fourteenth Amendments’ due process and equal protection
mandates, and under state constitutional principles as well (see Begel
1995: 93–97; Mehlman 1990: 378; but see Hirshfeld 1991: 2889–2890).
The Problem of Conflicting Guidelines
Supporting the early enthusiasm for CPGs was the notion that they
would ease the job of the courts in deciding medical malpractice cases
(Brennan 1991: 73). As mentioned above, getting at “the truth” in these
cases has traditionally involved a “battle of the experts,” with profes-
sionals on both sides offering opposing testimony as to the applicable
standard of care and the lay jury left scratching its collective head over
which of the two (or more) experts to believe. If there were a definitive
guideline, some theorists reasoned, the courts could simply treat that
guideline as setting the applicable standard of care. Even with the CPG
supplying the legal standard, there would still be challenging work for
the jury. For instance, there could be difficult factual questions as to 
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(a) whether the CPG proffered was appropriate to the case being liti-
gated; (b) if so, whether the defendant provider had complied adequately
with the CPG; (c) whether, if there was noncompliance with an applica-
ble guideline, the plaintiff’s harm resulted from that noncompliance; and
so forth. Nonetheless, having a single, definitive point of reference to fix
the appropriate standard of care would greatly simplify the judicial
process, largely by avoiding the traditional battle of the experts on that
critical issue.
Having a single authoritative guideline for each medical condition is
not likely to be, however. For one thing, achieving such unanimity would
require designating some entity, presumably a governmental agency, as
the sole arbiter of what is acceptable medical practice. That is practically
and politically inconceivable; the commitment to pluralism and compe-
tition is too deeply ingrained in the American spirit, to say nothing of per-
vasive distrust of government processes. Moreover, some health policy
experts have argued for encouraging competing practice guidelines as a
way of contractually reforming the health care system (Havighurst 1991:
93).
Accepting that there will almost certainly be multiple guidelines for
many conditions, courts will have to engage in a process of deciding,
when guidelines conflict on a material point, which one to treat as author-
itative, or more authoritative. This promises to be a daunting task. As
shown by the breast cancer screening example presented earlier in this
article, knowledgeable, respected professional groups can, and often do,
come down on opposite sides on a particular treatment issue. What
should be done when that happens? When two (or more) groups, and
thus their guidelines, are of equal stature and authority, a jury could be
instructed that the defendant physician acted acceptably if he or she fol-
lowed either guideline. Such an instruction would closely mirror the
“two schools of thought” doctrine long recognized in numerous U.S.
jurisdictions (Furrow et al. 1997: 200 n. 3). It is closely related in concept
and application to the “respectable minority” doctrine discussed above. 
But what if the trial judge does not view the conflicting guidelines as
being of roughly similar stature or authority? What if there is a signifi-
cant difference between the apparent quality of the guidelines or between
the auspices from which the conflicting guidelines emanate? Should the
court then exclude the guideline of the lesser organization, or instruct the
jury to give greater weight to the treatment recommendations of the bet-
ter known or more respected organization? That hardly seems workable;
arguably it even violates due process by invading the province of the jury.
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What is likely to happen, then, is that, assuming both guidelines meet
minimum qualifications, they will both be admitted and the jury will be
left to choose between them—perhaps with adequate wisdom, perhaps
not. If the court regards one of the guidelines as not meeting the mini-
mum standard for admissibility, presumably it could and would exclude
it; but what criteria would it use in making that determination? If these
questions seem familiar, perhaps it is because they are issues raised by
the implementation of the Daubert decision, discussed by Shuman here.
Surely, a means to help courts sort out the problems posed by conflicting
guidelines would be a major contribution to the utility of guidelines and
the willingness of courts to deal with them. A governmental certification
program for clinical practice guidelines would seem to offer substantial
benefits in this regard. Before proceeding to lay out such a legislative
solution, however, it would be well to examine the underlying “politics”
of CPGs.
The “Politics” of Clinical Practice Guidelines 
As some commentators have recognized, the development and promo-
tion of EBM has important political dimensions. The rapidly evolving
science of outcomes assessment and its expanding application to the
everyday delivery of health care have the potential to change substan-
tially the dynamics and power relationships in the health care provider
community, affecting the prestige and pocketbooks of powerful vested
interests. Not surprisingly, there is an inherent cultural (some would call
it “political”) conflict between those who support EBM and those who
support continuance of the traditional regime in which individual physi-
cians’ subjective and independent judgment holds sway. The ripples from
this culture clash extend beyond health care practice and will surely
influence how the law deals with medical evidence. The cultural/politi-
cal dimension merits consideration here; and, in this regard, three addi-
tions to the literature in the 1990s offer useful insights. Consideration of
these insights, interesting in their own right, will also inform our later
exploration of the advisability and feasibility of a guidelines certification
program.
Knowing and Acting in Medical Practice
Sandra Tanenbaum’s 1994 article, “Knowing and Acting in Medical Prac-
tice: The Epistemological Politics of Outcomes Research,” describes the
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results of a small-scale study she conducted in a department of internal
medicine to discover how physicians reason about clinical care, learn
from their experiences and other information available to them, and pass
their knowledge on to their professional colleagues. Her study gives valu-
able indications as to whether physicians are likely to “buy into” out-
comes research and let its results influence their diagnostic and thera-
peutic decision making. She observes that, at a basic level, physicians
have two very different ways of processing information: “At the level of
clinical practice, realism and empiricism represent two approaches to
medical problem solving: deterministic and probabilistic. Deterministic
reasoning searches out mechanisms of illness and therapy, including eti-
ology, pathophysiology, and the mechanisms of action. Probabilistic rea-
soning draws on what past experience predicts, whatever the cause. The
probabilist plays the odds while the determinist imagines the process”
(Tanenbaum 1994: 30–31). 
Tanenbaum goes on to analyze the various ways physicians make
sense of what they experience in their clinical practice. She notes that
they tell “interpretive stories” about their cases, using a deductive rea-
soning process to distill their experiences into values that guide their
future treatment of patients and are passed on to their colleagues in ways
both informal (e.g., lunchroom conversations) and formal (e.g., grand
rounds, conference presentations, journal articles, etc.). Through these
processes, “Every doctor accumulates a vast and idiosyncratic knowl-
edge of medicine” (ibid.: 33, emphasis supplied). From these and several
other perceptive and intriguing observations, she concludes that physi-
cians’ decisions are not likely to be greatly influenced by outcomes
research. They are inclined to be distrustful of outcomes research stud-
ies and the conclusions drawn from them. Moreover, even when they
accept that the research findings are accurate in general, they tend to find
reasons to believe that their particular patient is atypical and, therefore,
merits treatment different from that which might normally be indicated
by the study results. To put it perhaps too simply, given the detail and
subtlety of her analysis, doctors are strongly inclined to hold to their
idiosyncratic views, even in the face of strong contrary research evi-
dence. “The clinical medicine I observed was essentially interpretive and
therefore irreducible to probabilities, no matter how rigorously derived”
(ibid.: 31). Tanenbaum’s analysis lays an important foundation for Gary
Belkin’s (1997) and Matthews’s (1999) observations regarding doctors’
skepticism about the kind of information that forms the core of evidence-
based medicine.
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The Technocratic Wish
Belkin’s article “The Technocratic Wish: Making Sense and Finding
Power in the ‘Managed’ Medical Marketplace” (1997: 509) discusses the
“technocratic wish,” which Belkin defines as “an appeal to objective mea-
sures to resolve contentious issues and/or clothe their resolution as sci-
entifically logical and natural.” In the arena of managed care, the tech-
nocratic wish takes the form of a search for a (seemingly, at least)
objective and verifiable rationale to justify the shift of control from an
entrenched medical elite to a new cadre of health services researchers,
MCO executives, and government policy makers. This latter group views
the country’s health care needs, and thus leans toward allocating its
health care resources, using a systems approach, looking at issues on a
macro rather than micro level, and employing population-based rather
than individual-based measures to assess the utility and cost-effective-
ness of health care inputs. To put it another way, the “technocrats” tend
to measure the success of health care activities by looking at their aggre-
gate effect on populations rather than on individual patients, contrary to
the clinician’s natural tendency to focus on the individual patient she or
he is currently treating.
To implement their health care philosophy, those who share the tech-
nocratic wish collect data from entire populations, crunch the numbers,
and express their conclusions as to what works best in terms of popula-
tion-wide statistics. Their methodology is more quantitative and, on the
surface, at least, more objective than medicine’s traditional way of
assessing the effectiveness of health care, that is, by cumulating the qual-
itative observations of individual physicians based upon their experi-
ences with individual patients. The first approach appears more objec-
tive, the latter more subjective, since with the latter every observation
must go through an individual physician’s personal, subjective filter
before becoming a data point in the analysis. Belkin (ibid.: 512) points
out, however, that the seemingly objective quantitative approach is vul-
nerable to a “subjectivity of objectivity.” In other words, researchers nec-
essarily make choices among the many different ways of constructing
scientific tests and measures and of interpreting and framing the results.
When the range of possible approaches is recognized, it can be seen that
analysis that appears to be objective and inevitable actually is a mosaic
of subjective choices. Thus the difference in objectivity between the new
approach and the traditional approach may not be as great as devotees of
the technocratic wish would have us believe.
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In Belkin’s view, managed care has embraced the technocratic wish in
its desire to find a rationale and a mechanism for standardizing medical
practice and reining in physicians’ natural inclination to treat each
patient as a special case. MCOs, health insurers, and federal health pro-
grams commonly seek to control, or at least guide, how physicians treat
patients by pointing to the results of outcomes research and asserting
that, by and large, this should determine what care is provided and how.
This approach obviously runs counter to the natural tendencies of physi-
cians described by Tanenbaum. Belkin’s analysis bears on our present
discussion by helping to address the question of how influential custom-
ary professional practice should be in setting standards for measuring
physician performance when the application of EBM methodologies
would point in a different direction. In other words, how much weight
should EBM be given when it comes into conflict with the traditional
dynamic of subjective judgment and physician autonomy—either the
autonomy of individual physicians or the collective autonomy of profes-
sional groups?
Practice Guidelines and Tort Reform. Building on Belkin’s analysis,
Matthews’s response, “Practice Guidelines and Tort Reform: The Legal
System Confronts the Technocratic Wish” (1999), describes the battle for
control of the health care system as one that pits the qualitatively ori-
ented clinician—the “artful practitioner,” as Matthews terms her—
against the quantitatively oriented scientist. Operationally, the contest is
between the subjective judgment of individual professionals derived from
and applied to case-by-case experiences and across-the-board rules dis-
tilled by health services researchers from “large n” studies. It is also a
contest between professional discretion and “cookbook medicine,”
between the “art” of medicine and cold, hard science. Tanenbaum, Belkin,
and Matthews all recognize a broad distinction between hands-on clini-
cians and the more data-driven types who tend to be drawn into the fields
of research medicine, health plan administration, and health policy for-
mulation. The conflict between their worldviews is mirrored in the face-
off between those who practice medicine in the trenches and those who
run MCOs, governmental health programs, and the federal health policy
process. 
As a side note, it is interesting to contrast the view of physicians put
forward in these three articles by Tanenbaum, Belkin, and Matthews
with that expressed by Paul Starr in his classic 1982 book, The Social
Transformation of American Medicine. Among Starr’s many keen insights
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is his observation—not all that profound in itself—that physicians as a
group acquired their prestige and power in large part by holding them-
selves out as men of science. Their devotion to the systematic, scientific
pursuit of truth set them apart from, and above, lesser members of soci-
ety. To now look in a more detailed and precise way, using the lens of the
three more recent commentators, and see physicians—at least the arche-
typal physicians, clinicians—cast not as scientists but rather as “artful
practitioners” with a bias against the emerging science of outcomes
research and EBM is, at first, surprising. Upon reflection, however, this
shift reveals something we all know, namely that things look different
from up close than they do from farther away or, to put it another famil-
iar way, that “all things are relative.” Clinicians may fall at the less rig-
orously scientific end of the physician spectrum, according to Tanen-
baum, Belkin, and Matthews; but don’t forget that the spectrum in
question is an array of scientifically oriented professionals. Therefore, it
is possible, and mostly accurate, to regard physicians on the whole as
people of science while, at the same time, noting vast differences among
this group in terms of their approach to science. Just as in George
Orwell’s Animal Farm some pigs were “more equal than others,” so in
the world of medical science some physicians are “more scientific” than
others.
Turning back to the difference of perspectives between medical practi-
tioners and those who run health plans and participate in the policy
process, it is apparent that this parallax reflects, and magnifies, the
underlying tension between doing the best for individual patients and
making the right systemic allocation choices for patients as a whole in
what is essentially a zero-sum game. The Benthamesque (social utilitar-
ian) goal of trying to achieve the greatest good for the greatest number
is often in conflict with the goal of trying to serve individual patients
unreservedly and rendering the best (although it is often the most expen-
sive) care for the individual without regard to the longer-term systemic
consequences.
Matthews’s article extends Belkin’s thesis by examining how the
courts’ treatment of CPGs can be expected to affect their adoption and
use by the medical community. His analysis supports the view, expressed
above, that allowing the use of CPGs only for defense purposes, as in
Maine and Minnesota,—was a political decision meant to stimulate the
adoption and use of guidelines by a physician community otherwise
reluctant to accept them, in part because of its fear of the liability conse-
quences. Getting physicians to rely upon and conform their practice to
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guidelines based on quantitative, empirical, outcomes research is chal-
lenging. Even more challenging is getting them to acknowledge this
reliance in a formal courtroom setting. As Matthews (1999: 287) observes,
for “most of the twentieth century, the legal system has validated the
medical profession’s belief that the authority of clinical judgment derived
from personally acquired disciplinary expertise.” For that reason, per-
mitting physicians to introduce evidence that they followed practice
guidelines is “not merely a technical change in the law; rather, it is 
using the regulatory function of law to facilitate the health economists’
construction of authoritative medical judgment based on the ideal of
impersonal and standardized objectivity, that is, the technocratic wish”
(ibid.). 
It is interesting to note that in speaking of the “regulatory function of
law,” Matthews posits that law has two broad functions: litigation, the
settlement of disputes, which is retrospective (backward-looking) in ori-
entation, and regulation, which is prospective (forward-looking). The
law’s regulatory function is much more compatible with the notion of
EBM, which casts things in probabilistic terms. Regulation, which looks
to the future, necessarily deals with what might happen, a probabilistic
notion, rather than trying to determine what actually did happen in a past
incident, the obvious focus in litigation. Since our focus here is on how
courts will deal with CPGs in a litigation situation, the tension between
the essentially probabilistic nature of EBM evidence and the determinis-
tic requirements of assessing and assigning responsibility for a past event
is at its greatest—or so Matthews might argue.
Matthews’s analysis addresses the factors that will dispose physicians
to use CPGs in litigation; but what about the factors that will dispose
courts to embrace them? Obviously, a court will admit CPGs as evidence
and use them in a particular way if directed to do so by the legislature;
but in the absence of a legislative mandate, what will courts be disposed
to do? Just as the medical profession is accustomed to relying on the sub-
jective opinions of physicians, courts have a long tradition of relying on
the testimony of medical experts to establish what is professional custom,
which, in turn, sets the legally required standard of care for the case at
bar. It is intriguing to ponder possible parallels between the opposing
mind-sets of the two groups described in the Belkin and Matthews arti-
cles and the mind-set of judges who will be called upon (still assuming
the absence of a legislative command) to decide how to treat CPGs when
they are offered as evidence. Presumably the reason that the law decided
many years ago to use professional custom as the basis for setting the
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legal standard of care, was that courts had no way to know what was the
proper treatment for a patient in a particular instance. The obvious solu-
tion was to look to the medical profession and assume that what it cus-
tomarily did was the right thing to do. Today, a judge might be faced in
such an instance with two proffers of conflicting evidence: one the tradi-
tional proffer of an expert witness who would testify how the profession
commonly treats such a case, the other a practice guideline proffered to
show the current EBM-based judgment as to what treatment works best
in such a case. How would the judge likely rule on the admissibility of
the latter type of evidence? If the evidence were admitted, how would the
judge likely instruct the jury to treat it? These questions recall earlier dis-
cussion as to the various ways CPGs might be treated by the courts.
However, the question here is not just what treatments are possible but,
rather, what would the court most likely be disposed to do?
One might answer, simply, that the court would do whatever legal
precedents require it to do. But, as Matthews’s (1999: 288–294) discus-
sion of a group of cases involving guidelines reveals, courts are not so
constrained by precedent that they have no choice in this matter; and
courts have gone in different ways when presented with that choice. As
Matthews (ibid.: 289) puts it, “Regardless of which party in the dispute
introduced the guideline, however, the litigation always casts the same
issues into especially bold relief: the conflict between the impersonal
objectivity of a guideline and the personalized expertise of the physician,
or the conflict between the guideline’s focus on general decision proce-
dures and the legal (and medical) profession’s focus on the particular
facts of the case under consideration.”
Might not judges in general be more disposed to rely on medical expert
testimony than on the more technocratic input, the guidelines? Given its
emphasis on precedent ( past decisions), the legal system is inherently
conservative and backward-looking. Therefore, since reliance on expert
testimony is the long-established norm, change can be expected to come
slowly. Moreover, law is much more a qualitative (verbal) than a quanti-
tative discipline; judges might be less comfortable relying, or instruct-
ing a jury to rely, on a guideline derived from quantitative, statistical
processes rather than on expert witnesses’ “interpretive stories.” On the
other hand, in the post-Daubert era, as Shuman articulates, federal judges
have a duty to ensure that juries are presented with scientific evidence
that is enlightening and not confounding. Even state court judges, who
are not directly touched by the Daubert ruling—except in those states
that have opted to follow Daubert—may feel more inclined than previ-
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ously to direct juries toward standard-of-care evidence that is more
definitive, authoritative, and clear. 
Does this mean that judges will favor the use of guidelines over the
testimony of expert witnesses? Not necessarily. This is currently an area
for speculation because, despite the academic work done to ferret it out,
there is scant evidence to date of how judges will react to this new form
of medical evidence. The only thing safe to say is that we cannot assume
courts, left to their own choice, will move toward greater use of CPGs. If
we want CPGs, and EBM generally, to have greater prominence in the
courts, legislative action is needed. Maine, Minnesota, Kentucky, Florida,
and a handful of other states have spoken, albeit not that fully and
clearly, on the subject of guidelines. Most states, though, have not yet
taken a position. This commentator, for one, believes that they should,
but with federal leadership. EBM approaches, including the development
and use of CPGs, are a better way of guiding the practice and progress
of medicine. The nation’s courts should be opened to the evidentiary use
of guidelines. If it takes legislation to assure that this will come to pass in
a timely fashion, a focused effort to promote such legislation seems the
right prescription.
The Implications of the Political Terrain
The following section proposes a certification program for CPGs. How
does the “political” terrain described above bear on the feasibility of such
a program? Some general observations can be made, and, frankly, they
offer little encouragement. If physicians are not disposed to accept the
notion of CPGs in general, they are not likely to welcome a proposal to
give guidelines a federal imprimatur and increased importance in the
courts, moves intended to stimulate greater development and adoption of
guidelines. In short, the terrain is not—at first glance, at least—all that
favorable. Let’s examine that terrain, though, as an architect might do in
considering what kind of house, if any, can be built upon a difficult piece
of land. Sometimes, as in the case of Frank Lloyd Wright’s Fallingwater,
a very serviceable and impressive edifice can be constructed on seem-
ingly inhospitable real estate.
If, as Tanenbaum observes, clinicians are inclined to distrust the sci-
ence underlying outcomes research, EBM, and CPGs, or to discount their
relevance to individual practice situations, and if, as Belkin and Matthews
contend, guidelines are largely seen as a mechanism for nonclinicians to
use in controlling clinicians, a guidelines certification proposal can expect
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a tough, uphill climb to passage. Three questions will help to measure the
steepness of the ascent. First, can physicians be brought to understand
that they have more to gain than to dread from CPG certification? Sec-
ond, how much political muscle can the clinician population exert against
the program’s passage? And third, where are the other political players in
this contest likely to come down on guidelines certification? 
In trying to identify the various political forces at work here and to
predict how they will react to a guidelines certification program, one of
Paul Starr’s early articles comes to mind. Long before his defining work,
The Social Transformation of American Medicine (1982), Starr recog-
nized the interplay of professional, business, and public interests that sets
the stage for legislative action. In “Malpractice: The Doctor’s Discom-
fort,” published in the New Republic in 1975, he explained how, and why,
physicians and other health care providers, liability insurers, the legal
profession, and the general public would position themselves around the
countless legislative programs being put forward to correct the so-called
medical malpractice crisis of the 1970s. His words, although addressed to
a somewhat different issue, seem just as apt in the present context:
A crisis of any kind is a moment of potential discontinuity in social
affairs, simultaneously a danger and an opportunity: a danger to the
orderly operation of a social system but also an opportunity for those
who wish to change it in some way. For this reason, crises are not
always resisted; on the contrary, they are often welcomed. A crisis can
be a truly marvelous mechanism for the withdrawal or suspension of
established rights, and the acquisition and legitimization of new priv-
ileges. The power to create crises (and the opportunities they bring)
and, just as important, the power to define them are not distributed
equally in society. Some groups are better positioned than others to
promote their conception of events and to enlarge their discomforts
into social concerns. This is the case with the malpractice crisis. It is
the malpractice problems of physicians and insurers, rather than those
of patients, that now constitute a crisis. This is a reflection not so much
of the relative seriousness of their difficulties as of their relative power
to turn private into public troubles.
These two groups, the physicians and insurers, along with the legal
profession, dominate the current situation. Within this triad, all the
terms of debate are set. Whatever the resolution of the current crisis,
it will almost certainly have to satisfy the interests of the three domi-
nant parties. Less certainly will it have to satisfy the interests of the
public. The public has no clear conception of what its interests are,
354 Journal of Health Politics, Policy and Law
JHPPL 26.2-07 Rosoff  3/22/01  12:16 PM  Page 354Journal of Health Politics, Policy and Law
Published by Duke University Press
whereas the three dominant parties most emphatically do. (Starr 1975:
17)
The players are somewhat different in the current context from that
described above, but physicians are still squarely in the middle. Their
voice is powerful and is heard not only from their own mouths but from
those of their patients, who still, even in this age of diminished physician
dominance, derive much of their view of the health care system from
talking to their physicians. The current “backlash against managed care,”
which has political reverberations all the way up from the local to the
presidential level, is substantially driven by physicians interpreting to
their patients what is happening on the health care scene. If physicians
feel threatened by the guidelines movement, they will see to it that their
patients perceive it as a threat to them as well. “Cookbook medicine,”
especially if its recipes are being written by “the folks who brought you
managed care” and endorsed by “big government,” can easily be made to
seem very threatening to the general public. The chief lesson from all this
is simple and straightforward: physicians’ opinions matter. If they are to
throw their weight behind a guidelines program—not just to pass it but
to embrace it in the ongoing fashion needed to make it work—they will
have to be courted. The courting, however, should not take the constitu-
tionally and ethically questionable form of “one-way street” legislation
that allows use of guidelines only by and for the defense. It should, and
must, be based substantially on education. Physicians must be shown
how guidelines can work in their favor, not just against it, as they are
inclined to believe currently.
A Certification Program for Clinical 
Practice Guidelines?
In a 1995 article, I floated as a “trial balloon” the possibility of establish-
ing a federal program for certifying clinical practice guidelines (Rosoff
1995: 394). Now, five years later, the idea still appeals to me as a good
way of spurring the development and acceptance of high-quality guide-
lines and of aiding the courts in making determinations involving qual-
ity-of-care and entitlement-to-benefits issues. As the use of CPGs con-
tinues to grow, courts will inevitably encounter them in proffers of proof
by one or both sides in health care lawsuits. Except in the few states (e.g.,
Maine, Minnesota, and Florida, to name the most prominent) that have
enacted legislation on the subject, judges will have no guidance on how
to deal with them. As in past instances of case-by-case doctrinal devel-
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opment, they will cast about to find the right approach; and, presumably,
they will eventually devise workable rules. However, the time, effort, and
other costs of having this process be one of uncoordinated activity in the
state courts are hard to justify. A CPG certification program, coupled
with some direction to courts as to how to handle both certified and
uncertified guidelines, could surely reduce the valuable resources that
might otherwise be expended in this process—to say nothing of the false
starts and mistakes, and possible injustices to litigants, along the way. 
What is needed is a governmental certification program to give guid-
ance to the courts in two main dimensions: first, in distinguishing guide-
lines entitled to full credibility and weight from those not as deserving
and, second, in deciding what evidentiary weight to accord guidelines
falling into each of these categories. One thing should be made clear at
the outset: this proposal does not intend to be prescriptive about medical
practice. It contemplates that there can, and should, and will, be multi-
ple guidelines for given conditions. Any body (or anybody; in theory, it
could be an individual as well as an entity) that wants to submit a guide-
line for certification may do so. The result envisioned would be a free-
market competition in guidelines, but with a governmental “seal of
approval” that makes it easy to identify a valid guideline. It would be pos-
sible for multiple, conflicting guidelines to be certified; and uncertified
guidelines would have their place too, albeit a much less favored place.
The program would not, I repeat, have government decree how patients
should be treated or limit the advance of medical knowledge by enshrin-
ing the current state of practice in a bureaucratic orthodoxy. Nor would
the program increase the exposure of physicians and other healthcare
providers to litigation. To the contrary, it would lessen the need for liti-
gation and, when litigation does occur, it would make it simpler, more
efficient, and less costly. Notwithstanding that, in my view, the program’s
benefits would substantially outweigh its costs, I am under no delusion
that it will meet with ready acceptance. Numerous issues and objections
can be raised and inevitably will be. The more obvious and important of
these are identified and addressed below.
Basic Concept and Operation of the
Certification Program
Stated most simply, the proposal described more fully below calls for the
establishment of a federal certification program for clinical practice
guidelines, operated out of the Department of Health and Human Ser-
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vices (HHS), presumably by the Agency for Healthcare Research and
Quality (AHRQ). The agency running the program would have respon-
sibility for vetting, certifying, supervising periodic updating, and helping
to promote the dissemination and adoption of CPGs. The program would
be voluntary and open to any person or entity wishing to put a guideline,
or set of guidelines, forward for certification. Basic, fixed costs of run-
ning the program would be funded through the federal budget; variable
costs would be covered through fees charged to those submitting guide-
lines for review. The process of certification would involve not just gov-
ernment personnel but also representatives of the provider and consumer
communities. Certification, the federal “seal of approval,” would give a
guideline greater credibility, making it more “saleable” in the health care
marketplace and would also entitle it to special treatment in federal
and/or state courts in litigation involving quality-of-care and entitlement-
to-benefits, or coverage, claims. Essentially, a certified guideline would
be accepted by the courts as setting the legal standard for acceptable
quality of care in a malpractice suit, or for determining in a coverage dis-
pute whether a given treatment was medically appropriate. Since fixing
the applicable standard of care is a core issue in most malpractice and
coverage litigation, providing a simpler way to resolve this issue would
significantly streamline the litigation process, saving time and money for
all involved.
Who Should Do the Certifying?
Certification of guidelines could be done on the private or public level
and, if on the latter, by either a state or a federal agency. The last of these
alternatives clearly seems to be the best. Accreditation programs run by
nongovernmental entities—such as the National Commission on Quality
Assurance (NCQA), which accredits managed care organizations, and
the Joint Commission on the Accreditation of Healthcare Organizations
(JCAHO), which accredits hospitals and other institutional providers—
have been used as adjuncts to governmental regulation for many years
and have a commendable track record. However, although the success of
entities such as NCQA and JCAHO shows that private organizations can
contribute importantly to the definition and safeguarding of the quality of
care, because the proposed CPG program contemplates application of its
output in the courts, it is simpler and more certain to have a single, gov-
ernmental agency setting and implementing the standards for certifica-
tion. The main purpose of certifying guidelines is to help courts distin-
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guish those that are valid and credible from those that are of question-
able merit. Having a single, official certification process best supports this
objective; having multiple certification processes and standards would
reintroduce complexity and uncertainty into the situation and would thus
be counterproductive.
Assuming, then, that a government certification program is the pre-
ferred approach, should the process be handled at the state or federal
level? Some have advocated state programs over a federal program, at
least as an initial step (Trail and Allen 1995–96: 250). However, even
though a few states, such as Maine, have taken on the burdens of certify-
ing guidelines (24 Maine Revised Statutes Annotated, Section 2973), the
task ultimately is too large and complex to be administered effectively
at the state level. To handle not just the initial certification of guidelines
but also periodic updating to recognize and incorporate advances in sci-
entific knowledge and medical practice, there would have to be a highly
skilled core staff for whom review of guidelines was their main activity.
Maintaining consistently high-quality certifying agencies at the level of
the several states would be problematic. Furthermore, the waste and
redundancy inherent in duplicating certification activities in the states,
increasing cost not just for the states but also for guidelines issuers and
users, many of which are national in scope, makes a state-level process
highly undesirable. Finally, with a state-level process would come the
possibility that a guideline certified in one state might be disapproved in
another, opening the door to the very kind of sorting-out confusion the
certification program is intended to avoid. Despite the obvious negatives
to state-level certification, states would still be allowed to engage in this
activity if they so chose; in fact, it is hard to conceive how they could be
barred from doing so. It is unlikely, however, that many states would
choose to undertake this complex, labor-intensive, and expensive activity
if a federal program were in place. If some states did, they would at least
have the federal model to look to for guidance.
Assuming that a federal-level program is the way to go, an existing
entity, AHRQ, a unit within the HHS, is the obvious choice to perform
the guideline-certifying function. This choice acknowledges AHRQ’s core
mission and its substantial contributions over more than a decade—
largely under its former name, the Agency for Health Care Policy and
Research (AHCPR)—toward developing and refining the methodology
for generating CPGs. It also recognizes AHRQ’s recent efforts, with
ECRI (known in the 1960s as the Emergency Care Research Institute), a
nonprofit healthcare research organization based in suburban Philadel-
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phia, to compile and maintain an extensive on-line database of practice
guidelines, the National Guidelines Clearinghouse (NGC).3 In fact, a
Web-accessible database like the NGC, and the organizational infra-
structure to support it, is a sine qua non for a workable certification pro-
gram, further confirming the appropriateness of looking to AHRQ. 
It should be clearly understood that, while AHRQ would provide lead-
ership and technical assistance in the development of guidelines, and
would work closely with CPG developers, it would not develop guide-
lines on its own. Private-sector activities supporting the development of
CPGs should be encouraged and relied upon to the fullest extent practi-
cable. Moreover, nongovernmental parties representing professional
interests and the health care–consuming public should be involved in the
review of guidelines. The government’s role in defining standards for
medical practice should not extend beyond what is necessary to assure
the safe and sensible development and application of CPGs. 
Should Certification Be Mandatory or Voluntary?
The guidelines certification program should be voluntary. In fact, it is
hard to imagine how a mandatory program would work. The FDA (Food
and Drug Administration) process for reviewing the safety and efficacy
of drugs is mandatory, in that no manufacturer is allowed to market drugs
that have not been approved. But given the pervasiveness of guidelines
and the infinite number of forms they can take, it would hardly be possi-
ble to say that no guidelines can be used unless approved by the govern-
ment. In a voluntary program, the decision to seek certification of a CPG
would rest entirely with its issuer, as is presently the case when a guide-
lines issuer elects to submit its CPG for inclusion in the NGC database.
The incentive to seek certification would be great, however, as there
would be benefits to having one’s CPG certified, especially with regard to
the way certified guidelines are treated in the courts. As discussed below,
courts would be directed by legislation to treat certified CPGs as setting
the applicable standard of care in cases involving quality of care or cov-
erage under health plans. 
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The Criteria for Certification
To be certified, a CPG would have to be developed: (1) through rigorous,
scientific outcomes research, based upon an appropriate and adequately
large set of clinical practice data; (2) using appropriate methodology, as
defined by AHRQ regulations; (3) with input from qualified medical pro-
fessionals; and (4) with provision for frequent updating, to incorporate
advances in medical knowledge generally as well as experience gained
through clinical practice using that particular CPG. Guidelines develop-
ers would be required to maintain an efficient system for the ongoing
monitoring and evaluation of experience with the clinical use of their
guidelines. This would be similar, in concept at least, to the mechanism
by which the FDA requires pharmaceutical manufacturers to track clini-
cal experience with their newly approved drugs.
A further requirement for certification would be that the guidelines
must be well written; they must be sufficiently clear and easy to follow
that clinicians and others seeking to use them can do so confidently and
safely. Just as there is a science to developing the content of CPGs, there
is an art to expressing that content coherently. Here the expertise of
AHRQ would necessarily be brought to bear; a guideline that the review-
ers could not understand would hardly pass muster.
The Significance of Certification
Certification of a guideline would offer a number of benefits to its devel-
oper and to those who used it. First, the credibility bestowed by the gov-
ernmental imprimatur, an assurance that the guideline was properly
developed and well expressed, would assist the developer in getting peo-
ple to adopt it. If the guideline were being developed for sale—for exam-
ple, by an outcomes research organization that used EBM methodologies
to write cost-containing guidelines for use by MCOs—the developer
could command a better price for a certified guideline, in large part
because of the way courts would treat a certified CPG as compared with
one not certified. A certified guideline would be admissible in court as
evidence of the appropriate standard of care without further proof of
validity. Moreover, compliance with a certified guideline would raise a
presumption of proper care. 
To offer a concrete example, suppose an HMO were to disseminate to
its participating physicians a guideline that called on them to use more
sparingly an expensive test that previously had been in routine and 
frequent use. Assume that this cost-reducing guideline was based on
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recently completed outcomes research that showed that conventional,
more liberal use of this test wasted resources without yielding a dis-
cernible benefit in terms of patient outcomes. The HMO could gain a sig-
nificant cost-competitive advantage by promoting less frequent use of the
test, but its participating physicians might well be concerned that if one
of them happened to experience a bad result apparently associated with
departure from standard practice, the physician’s deviation from the pro-
fessional community standard of practice would expose him or her to
malpractice liability. The court’s direction to regard compliance with a
certified guideline as proof—either conclusive or rebuttable proof that
the care rendered was adequate and thus not tortious—would be a pow-
erful counterforce to the physician’s reluctance, on legal grounds, to
depart from traditional overuse of the test. This hypothetical example
reflects, by the way, a fundamental, recognized purpose of CPGs, to help
overcome the resource-wasting phenomenon of “defensive practice of
medicine” (Daly 1995). 
As to whether compliance with a certified guideline should raise a con-
clusive or a rebuttable presumption of adequate care, arguments can be
made for either position. A conclusive presumption would effectively
give certified guidelines the force of law and would be the simpler
approach. Proof of compliance—or proof of noncompliance if the guide-
line were being used by the plaintiff for inculpatory, or “sword,” pur-
poses—would end the inquiry as to the adequacy of the care given. This
approach seems too pat, however; and cases could arise in which justice
would demand further consideration. For example, suppose a patient suf-
fered harm when her physician followed a certified guideline that, it
could be proven, he knew was rendered arguably obsolete by recent sci-
entific findings but that he chose to follow anyway. (Assume, for exam-
ple, that a new guideline had been certified, as the defendant knew, but
the old guideline had not yet been retired.) Allowing compliance with the
older certified guideline to shield the defendant’s actions completely
would tend to chill the advance of medical knowledge, an acknowledged
danger of certification processes generally. Rebuttal of the presumption
of adequate care should be allowed, but should not be too easy, or else it
would undermine excessively the value of certification. A reasonable
middle position—perhaps along the lines of Senator Chafee’s 1993
health care reform proposal mentioned above—would be to let the pre-
sumption be rebutted but only by “clear and convincing evidence.” This
recognized standard of proof lies between the traditional civil standard
of “preponderance of the evidence” and the much stricter criminal stan-
dard of proof “beyond a reasonable doubt.”
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Unlike the Maine and Minnesota guidelines programs described
above, the proposed program would treat evenhandedly the parties to lit-
igation implicating CPGs. Plaintiffs should be allowed to use certified
CPGs on the same basis as defendants, eschewing the Maine/Minnesota
“shield-only” or “one-way street” approach. While CPGs may be more
useful to one party than the other in some circumstances, access to their
use and the basic procedural and evidentiary rules should be the same for
both. One important reservation to this principle should be noted, how-
ever: the presumption of proper care should prevail. Where two (or
more) certified guidelines were in conflict, with the plaintiff asserting
noncompliance with one (“sword” use) and the defendant relying upon
compliance with the other (“shield” use), the presumption that the defen-
dant’s care was adequate should be upheld. If the defendant health care
provider could show compliance with an appropriate, certified guideline,
he or she would be entitled to the presumption that the treatment ren-
dered was adequate to meet the legal standard of care, even in the face of
a contrary, certified guideline proffered by the plaintiff-patient. To apply
this to the breast cancer screening example above, if both the National
Cancer Institute’s guideline calling for biennial breast cancer screening
for women in a given age and risk category and the American Cancer
Society’s guideline recommending annual screening for this same popu-
lation were certified, the provider, the HMO in this case, would prevail.
Such treatment would be the functional equivalent of the “respectable
minority” doctrine currently applied in many U.S. jurisdictions. 
Note that, while this approach would greatly simplify the court’s job of
determining what standard of care to apply and would give the defendant
provider an important “benefit of the doubt,” it would neither answer all
questions nor assure the defendant of victory. In many cases, an impor-
tant issue might remain as to whether the guideline(s) proffered was
(were) appropriate to the facts at hand. No matter how much benefit of
the doubt was given to a particular CPG, it would not carry the day unless
it was found to be an appropriate guideline for the situation at bar. Like-
wise, there might be substantial factual dispute as to whether the guide-
line was, in fact, followed by the defendant and, if it was not, whether the
harm suffered by the plaintiff was caused by the defendant’s noncompli-
ance. The only thing changed by the guidelines certification program
would be the simplifying of the court’s search for the proper standard of
care to apply; but that one change would be a most significant contribu-
tion to the cause of judicial efficiency.
What treatment should be accorded to an uncertified guideline under
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this regime? This is a tricky question that deserves closer consideration
and debate before a firm position is taken. As a starting point, it seems
clear enough that a court should be able, in its discretion, to admit an
uncertified guideline into evidence if satisfied that the guideline meets
the criteria for validity specified in the certification program. Presumably,
courts would generally be disinclined to engage in such an inquiry; and
issuers and users of guidelines would be motivated to undertake certifi-
cation to avoid the uncertainty of not knowing how a given court would
react to their uncertified guideline. On the further question of what
weight and treatment to give certified as opposed to uncertified guide-
lines, things are less clear. Putting uncertified guidelines on substantial
parity with certified ones would undermine the incentive to seek certifi-
cation; however, discounting their evidentiary value too greatly would
belie the claim that the certification program is voluntary. Numerous
lesser questions can be raised. For example, if an uncertified guideline is
admitted, should the court allow inquiry into why it is uncertified? Is it
because the developer did not seek certification, or was it sought and
denied? Should the court allow the jury to be led through an exploration
of why it was denied? These are subtle questions indeed. In addressing
them, policy makers should keep in mind that a main purpose of promot-
ing the use of guidelines in the courts is to simplify and rationalize the lit-
igation process, not to add new and uncharted dimensions of complexity. 
One final, but very significant, point should be noted about the impli-
cations of certification. The developer and/or issuer of a CPG should be
immune from civil liability for harms caused by its adoption and use if
the requirements for certification have been met. This would seem to fol-
low logically and implicitly from the foundation principle that com-
pliance with a certified guideline shields the user of the guideline; but 
the implication for the guideline developer/issuer should be explicitly
acknowledged. Although it is unclear whether guidelines issuers might
be liable under current law, there has been scholarly speculation on the
issue (see e.g., Brennan 1991: 78–81; Rosoff 1995: 91–93), and the pos-
sibility is real enough to provide additional motivation to issuers to seek
certification. 
The Costs of a Certification Program
The proposal is simple to state on this point: general costs related to
AHRQ’s activities as the certifying agency should be borne by the federal
budget. Reasonable costs of initial certification, and of periodic recertifi-
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cation, should be borne by the entity issuing the CPG. This approach
roughly follows that used by the FDA in its approval process for drugs
and medical devices; and there is ample precedent to be found in other
federal regulatory programs as well. A more detailed analysis of the
likely costs of a federal guidelines certification program with both the on-
budget and off-budget costs is beyond the scope of this essay but would,
of course, be an important consideration in any legislative debate about
adopting such a program.
The Challenges of Implementation
The guidelines certification program proposed here poses a number of
challenging issues, not the least of which is the daunting task of gaining
sufficient support within the administration and in the Congress to have
it put forward and enacted. Without meaning to minimize that concern,
the simple answer is that it is beyond the scope of this essay. In any
event, unless some consensus can be developed that a certification pro-
gram of the type proposed is worth having, there is little point in strate-
gizing about how to get it passed. 
Assuming adequate political support for a certification program of the
type envisioned, a central question is how its proposed impact on state
law and state court processes would be achieved. One would hope, of
course, that states would see the value of the certification program and
would want to support it through their court systems without any com-
pulsion. If this were not the case, at least with particular states, other
means of attaining state participation would have to be sought. This is
certainly not a trivial problem. While a full treatment of this issue would
extend the article well beyond the constraints of this symposium, it
would be cavalier not to address it, at a basic level at least. 
Both the provision of health care and the operation of the insured and
employer-self-funded plans that pay for much of it are so intertwined
with interstate commerce that Congress likely has the jurisdiction to reg-
ulate it under the commerce power of Article 1, Section 8, of the Consti-
tution. Regulation of health care–related litigation at the state level,
however, implicates state sovereignty concerns in a way that regulation
of health care alone does not. ERISA, the Employee Retirement Income
Security Act of 1974, provides a highly visible precedent for federal pre-
emption of state law in this area, although, in the view of many com-
mentators, it is not a particularly positive precedent (see, e.g., Mariner
1996, 2000). If implementation of the state law aspects under the federal
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Commerce Power is deemed too problematic, there is also the possibil-
ity of using the Spending Power, also under Article 1, Section 8. States
could be offered financial incentives for voluntarily participating in the
program, much as federal highway funding was tied in the 1970s to
states’ adoption and enforcement of the 55-mile-per-hour speed limit.
Finally, the certification program could be tied to other federal health
care programs, principally Medicare and Medicaid, loosely following the
precedent established by the Emergency Medical Treatment and Active
Labor Act of 1985 (EMTALA), which requires hospitals participating in
Medicare to provide urgent care to all of their patients, not just those
with Medicare coverage. There are numerous other examples of federal
health care initiatives being successfully implemented at the state level
either through the Commerce Power (e.g., the 1974 Health Care Amend-
ments to the National Labor Relations Act, Pub. Law 93–360, codified
in Section 152 of Chapter 42 of the U.S. Code) or an artful use of “carrot
and stick” mechanisms (e.g., the National Health Planning and Resources
Development Act of 1975, Pub. Law 93-641, 42 U.S. Code, Section 300K
et seq.). Given this range of possibilities and precedents, it is fairly cer-
tain that the jurisdictional premises upon which the program rests can be
successfully handled. 
Assuming the program can be enacted, an important ongoing concern
is that the certification process not be allowed to freeze, or even chill, the
advance of medical knowledge and practice. This issue has been touched
on above and is not easily resolved. The program, as implemented, must
provide a prompt, efficient, and low-cost process not just for the review
of new guidelines but also for the timely updating and revision of approved
guidelines, including the decertification of guidelines known to be no
longer valid. There must be adequate budget to assure an ample number
of competent reviewers and an ongoing commitment to rapid turnaround
of materials submitted. The use of electronic submission of materials and
subsequent communication about them should be a significant help in
this regard.
Conclusion
Proposals for federal certification of clinical practice guidelines, includ-
ing not only my own freestanding proposal but also those contained in
the Clinton, Chafee, and other federal health care reform proposals, have
been “around” for over five years without attracting substantial attention
or support. This is true despite the growing acceptance and use of CPGs
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during this period. If anything, the continuing proliferation of CPGs
makes it more advisable that some mechanism be devised to introduce
guidelines more prominently into the legal process and help courts
decide which guidelines should be regarded as authoritative. I hope this
present restatement and more detailed reexamination of my proposal in
the context of this larger consideration of EBM will help to raise aware-
ness that the time for a national guidelines certification program has
come—or, at least, is on its way. 
If the above general principles and specific elements can be fashioned
into a national framework for the certification of clinical practice guide-
lines and a rationalized approach to their use in the courts, I believe the
expanded use of CPGs it will enable will bring substantial benefits to our
health care system. While there will always be a need and a place for
professional medical judgment, we should make maximum use of avail-
able empirical evidence as to what works and doesn’t work, synthesizing
that data into carefully analyzed, widely disseminated guidelines to
assist physicians to properly apply their clinical judgment. Benefits will
flow to the legal system as well, making possible more accurate, efficient,
and affordable resolution of disputes about the quality and appropriate-
ness of health care provided. 
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